The use of natalizumab for multiple sclerosis

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 3 X users
facebook: 2 Facebook pages

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 197 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 5 news stories from 5 outlets.

FDA approves first natalizumab biosimilar for MS treatment

Medical News Today, 30 Aug 2023

Share on PinterestTyruko, a biosimilar of Tysabri, has now been approved by the FDA for the treatment of MS.

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

BioTech Gate, 03 Sep 2019

Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitti…

News story from Finanz Nachrichten on Tuesday 03 September 2019

Finanz Nachrichten, 03 Sep 2019

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

Benzinga, 03 Sep 2019

Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitti…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 1 additional news stories.